Nyxoah SA (NYXH) News
Filter NYXH News Items
NYXH News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NYXH News Highlights
- NYXH's 30 day story count now stands at 2.
- Over the past 7 days, the trend for NYXH's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about NYXH are SA and LAW.
Latest NYXH News From Around the Web
Below are the latest news stories about Nyxoah SA that investors may wish to consider to help them evaluate NYXH as an investment opportunity.
Information on the total number of voting rights and sharesREGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), February 11, 2022, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the belowinformation following the exercise of subscription rights and the issue of new shares. Share capital: EUR 4,431,664.69 Total number of securities carrying voting rights: 25,797,3 |
Nyxoah to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceNyxoah to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference Mont-Saint-Guibert, Belgium – February 4, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conf |
Nyxoah Provides General Corporate UpdateNyxoah Provides General Corporate Update Transformational 2021 positions Nyxoah for further clinical, regulatory, and commercial milestones in 2022 Mont-Saint-Guibert, Belgium – January 10, 2022, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today provided a general corporate update. 2021 Highlights Implant |
Nyxoah Announces Participation in the Piper Sandler 33rd Annual Virtual Healthcare ConferenceNyxoah Announces Participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference Mont-Saint-Guibert, Belgium. – November 12, 2021, 10:30 pm CET / 4:30 pm ET - Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Olivier Taelman, Chief Executive Officer, will participate at the Piper Sandler 33rd Annual V |
Nyxoah appoints new CFONyxoah appoints new CFO Mont-Saint-Guibert, Belgium – November 8, 2021, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Loïc Moreau will join Nyxoah as CFO as of January 1, 2022. Loïc will join Nyxoah from GSK, where he held leadership roles in Finance across various geographies. Prior t |
Nyxoah Announces Participation in the Stifel 2021 Virtual Healthcare ConferenceNyxoah Announces Participation in the Stifel 2021 Virtual Healthcare Conference Mont-Saint-Guibert, Belgium. – November 3, 2021, 10:30 pm CET / 4:30 pm ET - Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Olivier Taelman, Chief Executive Officer, will participate at the Stifel 2021 Virtual Healthcare Conference o |
Nyxoah Announces CE-Mark Indication Approval to Treat Complete Concentric Collapse (CCC) PatientsINSIDE INFORMATIONREGULATED INFORMATION Nyxoah Announces CE-Mark Indication Approval to Treat Complete Concentric Collapse (CCC) Patients Notified Body DEKRA approves IFU changes to remove warning regarding CCC patients Mont-Saint-Guibert, Belgium – October 4, 2021, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea |
Nyxoah Announces U.S. FDA Breakthrough Device Designation Granted for the Genio® System for Obstructive Sleep Apnea and Complete Concentric CollapseINSIDE INFORMATIONREGULATED INFORMATION Nyxoah Announces U.S. FDA Breakthrough Device Designation Granted for the Genio® System for Obstructive Sleep Apnea and Complete Concentric Collapse Mont-Saint-Guibert (Belgium), September 14, 2021, 8:00 am CET / 2:00 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that |
Nyxoah Announces Participation in the Cantor 2021 Virtual Global Healthcare ConferenceNyxoah Announces Participation in the Cantor 2021 Virtual Global Healthcare Conference Mont-Saint-Guibert (Belgium), September 13, 2021, 10:30 pm CET / 4:30 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Olivier Taelman, Chief Executive Officer, will participate at the Cantor 2021 Global Healthcare Conf |
Nyxoah Announces Participation in the Baird 2021 Global Healthcare ConferencePRESS RELEASE Nyxoah Announces Participation in the Baird 2021 Global Healthcare Conference Mont-Saint-Guibert, Belgium – September 2, 2021, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Olivier Taelman, Chief Executive Officer, and Fabian Suarez, Chief Financial Officer, will particip |